BerGenBio ASA (LON: 0RU5)

Market Cap	24.07M
Revenue (ttm)	36.92K
Net Income (ttm)	-10.79M
Shares Out	n/a
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,996
Average Volume	568
Open	8.69
Previous Close	8.71
Day's Range	8.42 - 8.69
52-Week Range	0.08 - 8.69
Beta	n/a
RSI	44.96
Earnings Date	Feb 26, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RU5

Financial Performance

In 2023, BerGenBio ASA's revenue was 354,000, a decrease of -9.00% compared to the previous year's 389,000. Losses were -190.40 million, -36.98% less than in 2022.

Financial numbers in NOK